论文部分内容阅读
目的:探讨TBX2和P16蛋白在宫颈鳞癌组织中的表达及其与宫颈癌临床病理特征的关系。方法:采用免疫组织化学技术,检测60例子宫颈鳞癌、40例宫颈原位癌(CINⅢ)和20例癌旁正常宫颈上皮(NCE)中TBX2和P16蛋白的表达,分析其表达与宫颈鳞癌的临床分期、病理类型及有无淋巴结转移的关系。结果:TBX2在宫颈鳞癌、原位癌和NCE中的阳性表达率分别为86.67%、82.50%、30.00%;P16为88.33%、87.50%、0%。与NCE组比较,TBX2和P16在鳞癌组及原位癌组阳性表达显著增高有统计学意义(P<0.001);TBX2和P16的阳性表达率与临床分期、病理类型及有无淋巴结转移均有关(P<0.01);TBX2和P16在宫颈鳞癌的表达中呈正相关(r=0.66;P=0.039;P<0.05)。结论:TBX2和P16在宫颈癌组织中表达水平的上调,两者可能是宫颈癌发生、发展的促进因子,并为宫颈癌的早期诊断、治疗及预后提供依据。
Objective: To investigate the expression of TBX2 and P16 protein in cervical squamous cell carcinoma and its relationship with clinicopathological features. Methods: The expressions of TBX2 and P16 proteins in 60 cases of cervical squamous cell carcinoma, 40 cases of cervical carcinoma in situ (CINⅢ) and 20 cases of normal cervical epithelium (NCE) were detected by immunohistochemistry. The clinical stage, pathological type and the relationship between lymph node metastasis. Results: The positive expression rates of TBX2 in cervical squamous cell carcinoma, carcinoma in situ and NCE were 86.67%, 82.50% and 30.00% respectively; P16 was 88.33%, 87.50% and 0% respectively. Compared with NCE group, the positive expression of TBX2 and P16 in squamous cell carcinoma and carcinoma in situ were significantly increased (P <0.001); The positive rates of TBX2 and P16 were related to clinical stage, pathological type and lymph node metastasis (P <0.01). There was a positive correlation between the expression of TBX2 and P16 in cervical squamous cell carcinoma (r = 0.66; P = 0.039; P <0.05). Conclusion: The up-regulation of the expression of TBX2 and P16 in cervical cancer may be the promoting factor for the occurrence and development of cervical cancer, and provide the basis for the early diagnosis, treatment and prognosis of cervical cancer.